Group 1 - Xinhua Medical has received a Class III medical device registration certificate for its medical electronic linear accelerator, which is intended for radiation therapy of tumor lesions [1] - The product enhances Xinhua Medical's radiation therapy product line and strengthens its core competitiveness, but the market remains competitive with seven other companies having similar certifications [1] Group 2 - Notai Bio has formed a strategic partnership with Gulf Pharmaceutical Industries (Julphar) to supply semaglutide active pharmaceutical ingredients across 22 countries in the Middle East and Africa [2] - This collaboration allows Notai Bio to leverage Julphar's commercial sales strength in the region, potentially enhancing the company's brand recognition internationally [2] Group 3 - Wantai Bio's TB-IGRA test kit has been included in the procurement list managed by the United Nations Office for Project Services (UNOPS) for the StopTB Partnership [3] - This inclusion signifies international recognition for Wantai Bio's TB-IGRA test kit, enabling participation in UN and global multilateral procurement projects, which may positively impact the company's international market expansion [3]
诺泰生物与中东药企Julphar达成战略合作;万泰生物TB-IGRA检测试剂盒被纳入联合国项目事务署采购清单丨医药早参